Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03413644 · ClinicalTrials.gov registry record

Evaluation of ClearLLab Leukemia and Lymphoma Panels

A clinical trial of Leukemia-Lymphoma, sponsored by Beckman Coulter.

Completed
Registry status
482
Enrollment target
4
Study locations

NCT03413644 is a study of Leukemia-Lymphoma that has completed, run by Beckman Coulter. The registered enrollment target is 482 participants. The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03413644, a study of Leukemia-Lymphoma, has completed, sponsored by Beckman Coulter.

COMPLETED
Registry status
482 participants
Enrollment target
4
Study locations

Study Summary

Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Flow Cytometry

Study Locations (4)

Florida

  • NeoGenomics Laboratories, Inc. - Fort Myers

Alberta

  • Calgary Laboratory Services - Calgary

Ontario

  • London Health Sciences Center - London

Other

  • Munich Leukemia Laboratory - Munich

Trial Details

FieldValue
Enrollment Target 482 participants
Start Date 2017-11-14
Est. Completion 2018-04-27

Sponsor

Beckman Coulter

18 total trials

What the Registry Record Tells You About NCT03413644

The ClinicalTrials.gov registry entry for NCT03413644 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beckman Coulter, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia-Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Flow Cytometry is the first listed.

NCT03413644 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Alberta, Ontario.

Frequently Asked Questions

What is clinical trial NCT03413644 about?

NCT03413644 is a clinical study titled "Evaluation of ClearLLab Leukemia and Lymphoma Panels". Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.

What is the current status of trial NCT03413644?

This trial is currently completed. The enrollment target is 482 participants. The study started on 2017-11-14. Estimated completion is 2018-04-27.

What conditions does trial NCT03413644 study?

This clinical trial studies the following conditions: Leukemia-Lymphoma.

What interventions are being tested in trial NCT03413644?

The interventions under investigation include: Flow Cytometry (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03413644?

This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03413644 being conducted?

This trial has 4 study locations across Florida, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.